Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03008083
Other study ID # TARGET DAPT
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date January 10, 2019
Est. completion date October 2022

Study information

Verified date September 2020
Source Shanghai MicroPort Medical (Group) Co., Ltd.
Contact Ming Zheng, MD
Phone (86)(10)66513642-6229
Email mzheng@microport.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a prospective,multi-center, open-label, randomized controlled clinical trial,aims to assess the clinical noninferiority of 3 months (short-term) vs 12 months (long-term) of Dual Anti-Platelet Therapy (DAPT) in patients undergoing percutaneous coronary intervention implanted sirolimus target- eluting stent with abluminal grooves containing a biodegradable polymer (Firehawk™ stent). All participants met the inclusion criteria begin taking aspirin and open-label thienopyridine therapy before index procedure, and will be 1:1 randomized to 3 months or 12 month of DAPT at index procedure.


Description:

This study will recruit 2,446 subjects with stable coronary artery disease in no more than 40 research centers in China. All participants met the inclusion criteria will be 1:1 randomized to 3 months or 12 month of DAPT after implanting Firehawk™ coronary stent.Clinical follow-up will be carried out at 30 days, 3 months, 6 months, 12 months, 18 months, 2 years and 3 years after index procedure.The primary study endpoint is Net Adverse Clinical and Cerebral Events (NACCE), a composite of all-cause death, myocardial infarction (MI), cerebral vascular accident (CVA) and major bleeding (academic research consortium [ARC] definition and GUSTO definition) at 18 months. Subjects that complete of 18 months follow-up will be regarded as having completed the primary endpoint. The secondary study endpoints contain ARC defined stent thrombosis (ST) at all study time-points; NACCE at 30 days,6,12,24 and 36 months of follow-up;major adverse cardiovascular events (MACE),major adverse cardiovascular and cerebral events (MACCE),target lesion revascularization (TLR),target lesion failure(TLF),ST at 30 days,6,12 ,18,24 and 36 months of follow-up; major bleeding at 1, 3, 6, 12 ,18,24 and 36 months of follow up; as well as cost-effective at 18 months of follow-up.


Recruitment information / eligibility

Status Recruiting
Enrollment 2446
Est. completion date October 2022
Est. primary completion date December 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility General Inclusion Criteria:

- Age = 18 years;

- Subjects (or legal guardians) understand the testing requirements and procedures, and provide written informed consent;

- Subjects with symptomatic coronary artery disease or confirmed asymptomatic ischemia;

- Target lesion should be new lesion with visually estimated reference diameter =2.5 mm and =4.0 mm in autologous coronary artery;

- Subjects willing to accept PCI therapy and to implant Firehawk™ stent only;

- Left ventricular ejection fraction (LVEF) = 30%;

- Subjects willing to accept the trial plan calls for all subsequent evaluations.

Angiographic Inclusion Criteria:

- Target lesions must be new and have a visually estimated reference diameter =2.5 mm and =4.0 mm in autologous coronary artery;

- No limitations in target lesion length and number;

- The first target lesion must be able to successfully expand and implant Firehawk™ stent.

Clinical Exclusion Criteria:

- Subjects with ST-segment elevation myocardial infarction:

- Subjects having an organ transplant or waiting for an organ transplant

- Subjects receiving chemotherapy or going to receive a chemotherapy within 30 days after PCI

- Subjects undergoing chronic (over 72 hours) anticoagulant therapy (such as heparin and coumarin) other than acute coronary syndrome

- Subjects with abnormal counts of platelet and white blood cell (WBC) (investigator assess clinical significance combine normal reference range of laboratory)

- Subjects with confirmed or suspected liver disease, including hepatitis lab results

- Subjects with elevated serum creatinine level >3.0mg/dL or undergoing dialysis therapy

- Subjects with active peptic ulcer, active gastrointestinal (GI) bleeding or other bleeding diathesis or coagulopathy, or refused a blood transfusion

- Subjects with cerebral vascular accident (CVA) or transient ischemic attack (TIA) in the past 6 months, or with permanent nerve defects

- Subjects undergoing any PCI treatment in target vessels within 12 months prior to baseline

- Subjects planned to undergo PCI or CABG within 18 months after the baseline PCI

- Subjects with a history of any coronary endovascular brachytherapy treatment previously

- Subjects associated with drugs allergy (such as sirolimus, or structure-related compounds fluorinated polymers, thienopyridine or aspirin)

- Subjects being suffered from other serious illness (such as cancer, congestive heart failure), which may cause drop in life expectancy to less than 18 months

- Subjects with a history of drug abuse (such as alcohol, cocaine, heroin, etc.)

- Subject planned to undergo any operations that may lead to confuse with the programme

- Subjects participating in another study of drug or medical device which did not meet its primary endpoint

- Subjects planned to pregnant within 18 months after baseline

- Pregnant or breastfeeding women

Angiographic Exclusion Criteria:

- Target lesions with the following criteria: left main, saphenous vein grafts or arterial grafts, via saphenous vein grafts or arterial graft, and in-stent restenosis;

- Subjects with unprotected left main coronary artery disease (diameter stenosis >50%);

- Protected left main coronary artery disease(diameter stenosis >50% and undergoing CABG)with target lesions located in left anterior descending artery and left circumflex artery;

- Additional lesions of clinical significance possibly needing interventional within 18 months after enrollment..

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
3 months DAPT
Subjects will continue DAPT with P2Y12 inhibitors and Aspirin (ASA) up to 90 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.
12 months DAPT
Subjects will continue DAPT with P2Y12 inhibitors and Aspirin (ASA) up to 360 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.

Locations

Country Name City State
China Shanghai Zhongshan Hospital Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Shanghai MicroPort Medical (Group) Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Net Adverse Clinical and Cerebral Events (NACCE) In hospital and at 30 days, 3, 6, 12, 24 and 36 months after index procedure.
Other Major Adverse Cardiac and Cerebral Events (MACCE) In hospital and at 30 days, 3, 6, 12 ,18, 24 and 36 months after index procedure.
Other Stent Thrombosis (per ARC definition) the definite and probable stent thrombosis In hospital and at 30 days, 3, 6, 12 ,18, 24 and 36 months after index procedure.
Other Target Vessel Revascularization (TVR) In hospital and at 30 days, 3, 6, 12 ,18, 24 and 36 months after index procedure.
Other Target Lesion Revascularization (TLR) In hospital and at 30 days, 3, 6, 12 ,18, 24 and 36 months after index procedure.
Other Target Vessel Failure (TVF) In hospital and at 30 days, 3, 6, 12 ,18, 24 and 36 months after index procedure.
Other Target Lesion Failure (TLF) In hospital and at 30 days, 3, 6, 12 ,18, 24 and 36 months after index procedure.
Other Myocardial Infarction (MI,including Q-wave MI and non Q-wave MI) In hospital and at 30 days, 3, 6, 12 ,18, 24 and 36 months after index procedure.
Other Major bleeding (ARC definition and GUSTO definition) In hospital and at 30 days, 3, 6, 12 ,18, 24 and 36 months after index procedure.
Other Death (All cause, Cardiac, Non-cardiac) In hospital and at 30 days, 3, 6, 12 ,18, 24 and 36 months after index procedure.
Other Cardiac Death/ All Myocardial Infarction In hospital and at 30 days, 3, 6, 12 ,18, 24 and 36 months after index procedure.
Other Procedural Success At time of procedure up to 7 days in hospital
Other Minimal Lumen Diameter (MLD)(In-device, in-segment, proximal 5 mm and distal 5 mm) Instantly after index procedure
Other The Immediate Lumen Gain Instantly after index procedure
Primary Net Adverse Clinical and Cerebral Events (NACCE) A composite of all-cause death, MI, cerebral vascular accident (CVA) and major bleeding at 18 months At 18 months after index procedure
Secondary Cost-Effectiveness Ratio (CER) CER = [total medical care costs of anti-platelet therapy] / [number of participants without net adverse clinical and cerebral events (NACCE)] At 18 months after index procedure
See also
  Status Clinical Trial Phase
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Not yet recruiting NCT05669222 - The FAVOR V AMI Trial N/A
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Recruiting NCT05240781 - Zotarolimus vs Sirolimus Eluting Stent in High Bleeding Risk N/A
Recruiting NCT03378934 - Anti-platelet Effect of Berberine in Patients After Percutaneous Coronary Intervention Phase 4
Not yet recruiting NCT06025071 - Residual Inflammatory Risk-Guided colcHicine in Elderly Trial Phase 4
Withdrawn NCT04043091 - Coronary Angiography in Critically Ill Patients With Type II Myocardial Infarction N/A
Completed NCT02837744 - Studying Hemostatic Effect of Axiostat® Dressing on Radial Access After Percutaneous Procedure
Completed NCT03085823 - The All-comers Sirolimus-coated Balloon European Registry
Completed NCT02044146 - A Pharmacodynamic Study of a Personalized Strategy for P2Y12 Inhibition Versus Ticagrelor in Reducing Ischemic and Bleeding Risk Phase 2/Phase 3
Completed NCT03131271 - Effect of Ice Bag Application to Femoral Region on Pain in Patients Undergoing Percutaneous Coronary Intervention N/A
Completed NCT01156571 - A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX) Phase 3
Completed NCT01135667 - Prasugrel Versus Double Dose Clopidogrel to Treat Clopidogrel Low-responsiveness After PCI Phase 4
Unknown status NCT00751491 - Clopidogrel Versus Adenosin in Non Urgent Percutaneous Coronary Intervention (PCI) Phase 3
Completed NCT00725868 - Blood Endothelium Biomarkers to Predict Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention N/A
Completed NCT03708588 - Chewed Versus Integral Pill of Ticagrelor Phase 4
Completed NCT04163393 - R-One Efficiency For PCI Evolution With Robotic Assistance N/A
Recruiting NCT05554588 - Intrathrombus Thrombolysis Versus Aspiration Thrombectomy During Primary PCI N/A
Recruiting NCT06080919 - Plaque Modification And Impact On Microcirculatory Territory After Drug-Coated Balloon Percutaneous Coronary Intervention (PLAMI). N/A
Recruiting NCT05353140 - LAAO Versus NOAC in Patients With AF and PCI N/A